Advanced Genetic Systems, Inc. (AGS) is a drug discovery company dedicated to pioneering novel classes of antiviral therapeutics.
AGS has focused our drug discovery efforts on an under-explored target, the Ribonucleoprotein (RNP) complex. RNPs are composed of interactions between structural RNA and proteins. Targeting RNPs is challenging due to the multiple roles, dynamic conformations, and chemical instability of these complexes. To address these challenges, we have developed two key tools. First, AGS has built a robust cell-based screening platform dedicated to targeting this class of interaction. Second, AGS has developed novel chemical strategies including the assembly and screening of custom libraries tailored to the chemistry of RNPs.
AGS is developing an entirely new class of HIV therapeutic that is inherently less vulnerable to escape mutations by the virus, but can also be combined with other drugs to maintain effective treatment and enhance quality of life.
